This company listing is no longer active
AVEO Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-2.9%
Tasa de crecimiento de los beneficios
32.7%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | -14.6% |
Tasa de crecimiento de los ingresos | 51.0% |
Rentabilidad financiera | -100.7% |
Margen neto | -30.8% |
Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero AVEO Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 22 | 94 | -29 | 68 | 13 |
30 Jun 22 | 79 | -36 | 65 | 10 |
31 Mar 22 | 61 | -41 | 63 | 5 |
31 Dec 21 | 42 | -53 | 61 | 0 |
30 Sep 21 | 26 | -58 | 54 | 20 |
30 Jun 21 | 14 | -56 | 45 | 13 |
31 Mar 21 | 7 | -49 | 34 | 5 |
31 Dec 20 | 6 | -36 | 22 | 0 |
30 Sep 20 | 6 | -29 | 16 | 0 |
30 Jun 20 | 28 | -4 | 13 | 0 |
31 Mar 20 | 28 | 0 | 12 | 0 |
31 Dec 19 | 29 | 9 | 11 | 0 |
30 Sep 19 | 30 | 36 | 11 | 0 |
30 Jun 19 | 6 | -3 | 11 | 0 |
31 Mar 19 | 6 | 4 | 11 | 0 |
31 Dec 18 | 5 | -5 | 11 | 0 |
30 Sep 18 | 4 | -24 | 11 | 0 |
30 Jun 18 | 6 | -28 | 10 | 0 |
31 Mar 18 | 6 | -65 | 9 | 0 |
31 Dec 17 | 8 | -65 | 9 | 0 |
30 Sep 17 | 8 | -74 | 9 | 0 |
30 Jun 17 | 4 | -53 | 9 | 0 |
31 Mar 17 | 4 | -28 | 8 | 0 |
31 Dec 16 | 3 | -27 | 8 | 0 |
30 Sep 16 | 6 | -28 | 10 | 0 |
30 Jun 16 | 20 | -15 | 10 | 0 |
31 Mar 16 | 20 | -12 | 11 | 0 |
Ingresos de calidad: VPA1 is currently unprofitable.
Margen de beneficios creciente: VPA1 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: VPA1 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.
Acelerando crecimiento: Unable to compare VPA1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: VPA1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.1%).
Rentabilidad financiera
Alta ROE: VPA1 has a negative Return on Equity (-100.67%), as it is currently unprofitable.